Evidence map›Paper›PMID 39534598›Full record

ArticleFrontiers in immunology2024

Antiviral immune response against HTLV-1 invalidates T-SPOT.TB

Masatoshi Kimura, Kunihiko Umekita, Chihiro Iwao, Katsumi Kawano, Yuki Hashikura, Yayoi Hashiba, Toshihiko Hidaka, Kenji Sugata, Yorifumi Satou, Taiga Miyazaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masatoshi KimuraDivision of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Kunihiko UmekitaDivision of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Chihiro IwaoDivision of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Katsumi KawanoClinical Laboratory, University of Miyazaki of Hospital, Miyazaki, Japan.
Yuki HashikuraClinical Laboratory, University of Miyazaki of Hospital, Miyazaki, Japan.
Yayoi HashibaInstitute of Rheumatology, Miyazaki Zenjinkai Hospital, Miyazaki, Japan.
Toshihiko HidakaInstitute of Rheumatology, Miyazaki Zenjinkai Hospital, Miyazaki, Japan.
Kenji SugataDivision of Genomics and Transcriptomics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Yorifumi SatouDivision of Genomics and Transcriptomics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Taiga MiyazakiDivision of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: T-SPOT.TB Method: Among all of the HTLV-1-positive RD patients who visited our department between August 2012 and December 2022, 44 patients who were screened using T-SPOT.TB® were included in the analysis. QFT testing was performed in 33 of the 44 patients, and the results were compared with that of T-SPOT.TB®. Furthermore, we performed a culture experiment mimicking T-SPOT.TB® using peripheral blood mononuclear cells (PBMCs) obtained from HTLV-1-positive patients with RD. Additionally, T-cell subsets with autonomous product IFN-γ were analyzed using a flow cytometer. Results: Of the included patients, 13 (29.5%) were invalid for T-SPOT.TB® because of the increased number of negative control spots. The median HTLV-1 proviral load in the invalid group was higher than that in the valid group (2.45 vs. 0.49 copies/100 PBMCs, respectively, Conclusion: T-SPOT.TB® may be invalidated by the interaction between Tax-expressing CD4+ T-cells and cytotoxic CD8+ T-cells. Moreover, HTLV-1-associated immune reactions due to contact between these cells may be unlikely to occur in QFT using whole blood. Therefore, our results reveal the superiority of QFT over T-SPOT.TB® as a screening test for LTBI in HTLV-1-positive patients with RD.

Indexed as

HTLV-I InfectionsHuman T-lymphotropic virus 1Interferon-gammaRheumatic DiseasesAdultAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansInterferon-gamma Release TestsLatent TuberculosisLeukocytes, MononuclearMaleMiddle AgedInterferon-gammacytotoxic T lymphocytesHTLV-1IFN-γ-releasing assaylatent tuberculosis infectionrheumatic disease

Identifiers

PMID39534598
PMCPMC11554456

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.